title: [Indolent lymphomas: classification, clinical presentation and treatment]].
abstract: The malignant lymphomas comprise a heterogeneous group of neoplastic diseases of the lymphatic system. In the WHO classification 70 different entities are subdivided. Each type of lymphoma is defined as a disease with specific clinical characteristics, as well as morphological, immunophenotypic and genetic characteristics. The indolent lymphomas include follicular lymphoma, marginal zone lymphoma, Lymphoplasmacytic lymphoma, small cell lymphocytic lymhoma/chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. Indolent lymphomas are characterized by slow growth and a chronic course of the disease. Antibody-based therapies, have significantly improved the prognosis, nevertheless there is no curative treatment. Watch and wait is still an reasonable option in asymptomatic patients. The goal of therapy has been to maintain the best quality of life. and to avoid late toxicities. The following review presents the current treatment options.
authors.affiliation: Abteilung Onkologie-Hämatologie, Spitalzentrum Oberwallis, Brig. reinhard.zenhaeusern@hospitals.ch
authors.forename: Reinhard
authors.initials: R
authors.lastname: Zenhäusern
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008223:Lymphoma / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D010166:Palliative Care; D011379:Prognosis; D011788:Quality of Life; D033581:Stem Cell Transplantation; D014944:World Health Organization